When a pathogen breaches the initial barriers of the skin or a mucosal surface, both soluble and cellular innate defenses mechanisms are encountered and an inflammatory response is rapidly initiated. In the upper respiratory tract, mucous membranes covered with secreted mucous, provide an innate barrier to infections.
Reinforcing this barrier may be a good treatment strategy, for instance, by applying a formulated solution in form of mouth or nasal spray, an orosoluble tablet or powder. Moreover, if a compound with a demonstrated antiviral and antibacterial activity is added, the protection efficacy is even higher.

In Propolis M.E.D.® ORAL SPRAY, the combination of glycerol and Propolis M.E.D.® exerts a barrier function when applied to the pharyngeal mucous membrane. Glycerol, a natural humectant, attracts and retains nearby liquid and virus particles via absorption due to its high osmotic activity while Propolis shows a potent antibacterial and antiviral activity.

The antiviral activity of Propolis is the subject of numerous studies. From those studies it appears that the active components of Propolis can act both against DNA and RNA viruses directly and indirectly through immune-enhancer action and immunomodulation that lead to a virucidal effect.

In a recent study, researchers from University La Sapienza in Rome, have been studied the virucidal activity of Polyphenols from Propolis M.E.D.® on several different type of enveloped RNA viruses (including coronaviruses, such as Sars-Cov 2).
The concentrations tested in this study were the same used in Propolis M.E.D.® ORAL SPRAY that have been calculated starting from the effective dose able to resolve the symptoms related to upper respiratory tract infections in a randomized, placebo controlled clinical study on 122 subjects, recently published (Esposito et al. 2021).

In particular, the results from University La Sapienza indicated that the daily effective dose of Propolis M.E.D.® ORAL SPRAY, can significantly inhibit SARS-CoV-2 titer starting from 5’ time of contact. This virucidal effect is maintained up to 30 minutes (data under publication).

Similar results were obtained using the same concentrations of polyphenols from Propolis M.E.D.® against human low pathogenic coronaviruses (HCoV-OC43 and HCoV-229E) but also other enveloped viruses like Vesicular Stomatitis virus (VSV) or animal pathogenic coronaviruses (Feline coronavirus II (F-CoV-II).

Those important results, together with the well know antibacterial effect of Propolis M.E.D.® and efficacy demonstrated in previously published study on Influenza virus (Brakto et al., 2018) and herpes viruses (Demir et al., 2021) position Propolis M.E.D.® ORAL SPRAY as a product of choice for the treatment of respiratory infections of both bacterial and viral origin.

Come and meet us at CPhI Worldwide 2021